ArticleJournal of molecular structure2022
Anti-fibrillization effects of sulfonamide derivatives on
Open access · greenAbstract read
In one paragraph
Article in Journal of molecular structure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Novel Cocrystal of Quercetagetin: In vitro and in vivo Insights into Biopharmaceutical Performance.Pharmaceutical research · 2026Article
- In Vitro Evaluation of Amide-Linked Coumarin Scaffolds for the Inhibition of α‑Synuclein and Tau Aggregation.ACS omega · 2025Article
- Novel strategies for targeting tau oligomers in neurodegenerative diseases.Journal of neurology · 2025Review
- Inspecting the Triazole Scaffold as Powerful Antifibril Agents against 2N4R Tau and α-Synuclein Aggregates.ACS omega · 2025Article
- Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau.Bioorganic & medicinal chemistry · 2024Article
- Evaluation of Alpha-Synuclein and Tau Antiaggregation Activity of Urea and Thiourea-Based Small Molecules for Neurodegenerative Disease Therapeutics.ACS chemical neuroscience · 2024Article
- Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and α-synuclein fibrils.Bioorganic & medicinal chemistry · 2024Article
- 1,4-Diurea- and 1,4-Dithiourea-Substituted Aromatic Derivatives Selectively Inhibit α-Synuclein Oligomer FormationACS omega · 2024Article
- Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on α-Synuclein and Tau Aggregation.ACS chemical neuroscience · 2023Article
- Hyperphosphorylated tau (p-tau) and drug discovery in the context of Alzheimer's disease and related tauopathies.Drug discovery today · 2023Review
- Discovery of 4-aminoindole carboxamide derivatives to curtail alpha-synuclein and tau isoform 2N4R oligomer formation.Results in chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Jessica S FortinDepartment of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, United States.
Kazuma ShimanakaAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
A Prasanth SaraswatiDepartment of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, United States.
Mengyu LiuDepartment of Biochemistry and Molecular Biology, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States.
Kuang-Wei WangDepartment of Biochemistry and Molecular Biology, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States.
Hsiao-Tien HagarDepartment of Biochemistry and Molecular Biology, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States.
Soham MaityDepartment of Chemistry, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States.
Susantha K GanegamageNew Mexico Institute of Mining & Technology, Socorro, New Mexico 87801, United States.
Edmund EllsworthDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, United States.
Scott E CountsDepartment of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, United States.
Babak BorhanDepartment of Chemistry, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States.
Ulf DettmerAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, United States.
Min-Hao KuoDepartment of Biochemistry and Molecular Biology, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States.
Michigan State University · USBrigham and Women's Hospital · USPurdue University West Lafayette · USNew Mexico Institute of Mining and Technology · US
Funding
TAU, AB, SYNUCLEIN AND NITRATIVE/OXIDATIVE DAMAGE IN MCIP01AG014449 · NIA · UNIVERSITY OF PITTSBURGH · PI IKONOMOVIC, MILOS D · 1997 to 2024
$39.7MCentral noradrenergic mechanisms of cerebrovascular pathology in Alzheimer's diseaseR01AG060731 · NIA · MICHIGAN STATE UNIVERSITY · PI COUNTS, SCOTT E · 2019 to 2023
$2.4MStabilizing native α-synuclein homeostasis to prevent insoluble α-synuclein aggregatesR01NS099328 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2017 to 2021
$1.9MHyperphosphorylated tau aggregation kit to identify tauopathy risk factorR44AG057274 · NIA · CAYMAN CHEMICAL COMPANY, INC. · PI MORANO, MARIA INES · 2020 to 2021
$1.5MHyperphosphorylated tau aggregation-based Alzheimer’s disease early drug discoveryR01AG062435 · NIA · MICHIGAN STATE UNIVERSITY · PI KUO, MIN-HAO · 2019 to 2021
$1.3MSmall molecule inhibitors of hyperphosphorylated tau aggregation in Alzheimer's disease: lead optimization, and proof of concept in a rodent modelK08AG071985 · NIA · PURDUE UNIVERSITY · PI Jessica Fortin · 2022 to 2026
$822kContrasting pathomechanisms of membrane versus cytosol alpha-synuclein excessR21NS121826 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2021 to 2021
$505kSmall molecule inhibitors of hyperphosphorylated tau aggregation and cytotoxicity for the development of Alzheimer’s therapeuticsR21AG070447 · NIA · PURDUE UNIVERSITY · PI FORTIN, JESSICA · 2021 to 2022
$402kNIA NIH HHS K08 AG071985NIA NIH HHS P01 AG014449NIA NIH HHS R01 AG060731NIA NIH HHS R01 AG062435NIA NIH HHS R21 AG070447NIA NIH HHS R44 AG057274NINDS NIH HHS R01 NS099328NINDS NIH HHS R21 NS121826
Abstract
In contrast to A
Indexed as
Alpha-synucleinAlzheimer’s diseaseFibrilsHyperphosphorylated tauIsoform 1N4RNeuroblastoma cellsSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.